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which exclusion or inclusion of cost data beyond trial has
on estimates of incremental costs: £2,640 and 
 

 
£7,130
respectively. The impact on the CEAC is shown to be
profound e.g. for a critical ICER of £500, the probability
that the treatment is cost-effective is increased by 0.732 if
beyond-trial costs are included.
CONCLUSIONS: Producers and consumers of cost-effec-
tiveness evidence need to be aware of the potential prob-
lem of asymmetry observed in our study since these re-
sults may have significant consequences on decision-
making. Economic theory would suggest that the beyond-
trial components should be excluded from our base case
analysis since they will have had no bearing on the ob-
served number of STPs.
 
PMI6
 
ESTIMATING AND COMPARING RESOURCE USE 
AND COST OF G-CSF USE IN CHEMOTHERAPY 
WITH THE ACTIVITY-BASED COSTING (ABC) 
METHOD IN THREE SETTINGS
Annemans LJ
 
1
 
, Vanoverbeke N
 
2
 
, Caekelbergh K
 
2
 
,
Van Belle S
 
3
 
, Cocquyt V
 
3
 
, Standaert B
 
4
 
1
 
Ghent University, HEDM, Meise, Belgium; 
 
2
 
HEDM, Meise, 
Belgium; 
 
3
 
Ghent University Hospital, Gent, Belgium; 
 
4
 
Amgen 
Inc, Brussels, Belgium
OBJECTIVES: to develop a standard methodology which
describes, inventories and compares the activities associ-
ated with the management of neutropenia with G-CSF in
chemo-treated cancer patients in three different settings:
inpatient care, outpatient care and home care; to collect
cost information associated with these activities for cal-
culating a cost per administration of G-CSF from the hos-
pital and home-care perspectives.
METHODS: The case study was conducted in Belgium
where the three different settings are permanently active.
Structured interviews of key personnel working in each set-
ting were taken first to obtain a detailed overview of the ac-
tivities, the frequencies, the resources used and related links
to other departments involved when G-CSF is administered.
Activities that had a high frequency of performance (at least
weekly) were then selected. Time measurements of these fre-
quent tasks, each with a fixed start- and end-point, were
then determined. Unit costs for each resource used and la-
bor costs were obtained from the administrative units.
RESULTS: Detailed activities in G-CSF management
were identified and a “map” for the product use in each
setting was established. Time measurements provided the
basic information for labor costing. Belgian estimates for
the cost per G-CSF administration, excluding the drug
cost, was estimated at 7.4 Euro for inpatient care, 4.4
Euro for outpatient care and 4.2 Euro for the home-care
setting. The main cost driver was found to be the cost of
taking and analyzing blood samples in the inpatient set-
ting where the cost of monitoring neutropenia is high
compared to the other settings. Excluding these costs
may favor the cost of hospital administration of G-CSF.
CONCLUSION: The methodology developed using the
ABC-method of investigation helps to compare the same
activities performed in administering G-CSF in different
settings. It clearly identifies where potential improve-
ments are possible so as to ensure efficient management
of G-CSF administration.
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OBJECTIVES:
 
 To assess uncertainty in a cost-utility
analysis (CUA) of adjunct entacapone treatment with
levodopa among patients with Parkinson’s disease (PD).
The purpose of the study was to apply probabilistic sensi-
tivity analysis in the comparison of alternative treatment
strategies using second-order simulation methods.
METHODS: Two treatment alternatives of PD, i.e.
levodopa with or without entacapone, were compared in
a cost-utility analysis. A Markov model was constructed
based on data from phase III clinical trials of entacapone
and a naturalistic health economic study of PD. Second
order simulation and bootstrap methods were employed
to provide understanding of the uncertainty due to sam-
pling variation. Cost and utility parameters were drawn
from empirical distributions. Parametric distributions
were used in the generation of transition probabilities.
RESULTS: Using a bootstrap sample size of 200 and
1000 patients, joint distribution of the mean incremental
costs and mean incremental utilities were calculated and
displayed in the cost-utility plane. The results for a boot-
strap sample of 1000 patients were all clustered in the
quadrant IV that includes situations in which entacapone
treatment yields gain in QALYs and cost savings. How-
ever, there was more variation with the sample of 200
patients. 85.4% of the bootstrap replications were in
quadrant IV. 12.1% of the joint distribution fell into
quadrant III indicating cost savings at the expense of loss
in QALYs. Gain in QALYs at extra costs resulted in
2.1% of the observations. Only 0.4% of the simulated re-
sults indicated less QALYs and increased costs.
CONCLUSIONS: The simulation methods used provided
valuable information on the sensitivity of the results of the
CUA. The probabilistic sensitivity analysis used in this
study strengthened confidence in the conclusions that enta-
capone as an adjunctive treatment to levodopa is both cost
saving and increases the quality of life of PD patients.
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OBJECTIVES:
 
 To stimulate debate on the willingness of
purchasers to fund interventions with varying impact on
life years gained (LYG) and quality of life.
METHODS: The authors’ hypothesis is that, for two
health-care interventions (HCIs) with equal cost per qual-
ity adjusted life year (QALY) ratios, purchasers favour
the intervention that extends life, rather than the one that
improves quality of life.
RESULT: The list describes a conceptual framework for
assessing the relative benefit of a HCI according to its
ability to extend life or improve quality of life. Low LYG,
Low QALY  Limited Intervention, Low LYG, High
QALY  Lifestyle Intervention, High LYG, Low QALY 
Life Extending Intervention, High LYG, High QALY 
Optimal Intervention. If this hypothesis is correct it
means that there is a need for a new measure of health
gain that distinguishes between ‘life extending’ and ‘qual-
ity of life improving’ HCIs and that builds on the QALY.
As an interim step, the authors suggest that both QALYs
and LYG values be cited in future studies and a new ratio
be adopted. New Ratio  QALY  LYG As this ratio
tends towards 0, the HCI tends towards a ‘life extending
intervention.’ As this ratio tends towards infinity, the
HCI tends towards a ‘lifestyle intervention.’ Factors other
than QALYs and LYG influence purchasers and results
of this new ratio should be interpreted with caution.
CONCLUSIONS: LYG and QALYs are widely recog-
nized and respected measures of HCI effect and are fre-
quently used in economic evaluation. Viewed in isolation
the measures do not inform purchasers as to the nature of
the HCI effect, and a ratio of the two would help im-
prove this understanding. The authors would welcome
feedback from purchasers as to how useful this new mea-
sure would be in informing health-care resource alloca-
tion decisions.
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OBJECTIVE: The reliability of a computer program to au-
tomatically scan and interpret data from manually-coded,
data-collection forms was evaluated in a resource-utilization
study of patients undergoing total knee-replacement surgery
and receiving low molecular-weight heparin therapy to pre-
vent deep vein thrombosis.
METHODS: Detailed in-patient data was extracted by
technicians via manual chart review and recorded on 13-
page forms. To expedite the analysis, Teleform 6.2 was
used to design the data-collection form and later, to auto-
matically scan and interpret each form returned.
RESULTS: The reliability of this technology was evalu-
ated for the first 100 eligible-patient forms received. Of
all field entries, Teleform automatically processed 89.9%
without an operator verification prompt. The remaining
ambiguous fields were viewed and edited on screen by an
operator. Data for each completed form was then for-
warded to an output data set. The output data set records
were compared against screen images of the original data
forms to determine the reliability of this process. An aver-
age of 183 field entries was recorded for each patient and
scanned by Teleform. 99.0% of the fields in the output
data set matched completely with the handwritten field
entries on the original forms. This reliability varied
slightly with the type of field analyzed. Check box, date,
numeric, and alphanumeric fields had reliability scores of
100.0%, 99.8%, 99.6% and 96.5%, respectively.
CONCLUSION: This program shows promise for orga-
nizations that routinely collect information on hard-copy
forms, though the required learning curve and cost ham-
pers its value for the occasional user or for small projects.
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OBJECTIVE:
 
 The National Institute for Clinical Excel-
lence (NICE) is a UK government-funded body that re-
sponds to requests for guidance from the Department for
Health on the use of selected new and established tech-
nologies in the NHS in England and Wales. In March
2001 NICE published its “guidance to manufacturers”
for these submissions, essentially economic evaluation
guidelines for publicly-funded health-care services includ-
ing, but not restricted to, pharmaceuticals. This presenta-
tion analyzes the extent to which the NICE guidelines use
economics to contribute to the goals articulated in the
NICE documentation for health maximization and to re-
move unfairness in the availability of technologies under
a fixed NHS resource constraint.
METHODS: We analyze from an economics perspective
the problems giving rise to the need for guidelines, the
theoretical basis of the guidelines, and the implications of
the guidelines for health maximization and rectifying un-
fair availability.
RESULTS: The NICE guidelines fail to reflect important
economic aspects concerned with constrained health
maximization and unfair availability. The guidelines can-
not be expected to lead to maximization of health gain
from NHS resources and hence may fail to serve the
needs of NHS decision-makers. In addition, use of the
guidelines could result in continued expansion of expen-
ditures as predicted by economic analysis.
CONCLUSIONS: The guidelines aim to provide system-
wide solutions, based on standardized methods, to what
are essentially locally-based, non-standardized problems.
Although guidelines might be helpful in dealing with
matters of administrative process, the need for or ability
of such an approach to accommodate the intellectual
